Latest Breaking News On - Johno mascarenhas - Page 1 : comparemela.com

Investigators Set to Explore Selinexor Monotherapy or Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

Selinexor is under investigation as monotherapy and in combination with the JAK inhibitor ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

Johno mascarenhasDynamic international prognostic scoring systemAdult leukemia programTisch cancer instituteMyeloproliferative disorders programIcahn school of medicine at mount sinaiIcahn schoolMount sinaiBlood cancersMyeloid disordersMyeloproliferative disordersMyelofibrosis symptom assessment formAdv hematolJak inhibitor naive myelofibrosisXport mf 044Xport mf 034

Navtemadlin With Ruxolitinib Leads to SVR Benefit in TP53 Wild-Type Myelofibrosis

John O. Mascarenhas, MD, discusses the design and rationale of the KRT-232-109 trial, key findings from the trial, and potential future directions of the study.

New yorkUnited statesJohno mascarenhasEuropean hematology associationIcahn school of medicine at mount sinaiTisch cancer instituteHematology associationIcahn schoolMount sinaiBlood cancersMyeloid disordersPatients with primary or secondary tp53 wild type myelofibrosis who hada suboptimal response to ruxolitinibKrt 232 109 studyAdding navtemadlin to ruxolitinibTisch cancer institute

Educated Patient® MPN Summit Myelofibrosis Panel: May 20, 2023

Educated Patient® MPN Summit Myelofibrosis Panel: May 20, 2023
curetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from curetoday.com Daily Mail and Mail on Sunday newspapers.

United kingdomBrielle benyonJohno mascarenhasIcahn school of medicineMoffitt cancer centerRami komrokjiIcahn school

Educated Patient® MPN Summit Novel Drugs And Combinations for MF Presentation: May 20, 2023

Educated Patient® MPN Summit Novel Drugs And Combinations for MF Presentation: May 20, 2023
curetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from curetoday.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesJohno mascarenhasIcahn school of medicine at mount sinaiIcahn schoolMount sinaiEducated patientNew treatment space

Imetelstat Displays Early Efficacy in Myelofibrosis; Phase 3 Trial Is Underway

The first-in-class telomerase inhibitor imetelstat is poised to expand the myelofibrosis treatment armamentarium should it prove safe and effective in the newly initiated phase 3 IMpactMF trial.

New yorkUnited statesJohno mascarenhasIcahn school of medicine at mount sinaiBlood cancersMyeloid disordersIcahn schoolMount sinaiMyelofibrosis symptom assessment formPatients with myelofibrosisImpactmf trialIcahn school of medicine at mount sinaiImbark trial